Nano-delivery to the lung - by inhalation or other routes and why nano when micro is largely sufficient?

Adv Drug Deliv Rev. 2022 Apr:183:114173. doi: 10.1016/j.addr.2022.114173. Epub 2022 Feb 22.

Abstract

Respiratory diseases gather a wide range of disorders which are generally difficult to treat, partly due to a poor delivery of drugs to the lung with adequate dose and minimum side effects. With the recent developments of nanotechnology, nano-delivery systems have raised interest. In this review, we detail the main types of nanocarriers that have been developed presenting their respective advantages and limitations. We also discuss the route of administration (systemic versus by inhalation), also considering technical aspects (different types of aerosol devices) with concrete examples of applications. Finally, we propose some perspectives of development in the field such as the nano-in-micro approaches, the emergence of drug vaping to generate airborne carriers in the submicron size range, the development of innovative respiratory models to assess regional aerosol deposition of nanoparticles or the application of nano-delivery to the lung in the treatment of other diseases.

Keywords: Aerosol; Inhalation; Lung diseases; Nano-carriers; Nano-delivery; Nanomedicine.

Publication types

  • Review

MeSH terms

  • Administration, Inhalation
  • Aerosols
  • Drug Carriers
  • Drug Delivery Systems*
  • Humans
  • Lung
  • Nanoparticles* / therapeutic use

Substances

  • Aerosols
  • Drug Carriers